TY - BOOK ID - 139146573 TI - Rheumatoid Arthritis Therapy Reappraisal : Strategies, Opportunities and Challenges PY - 2020 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - rheumatoid arthritis KW - sleep KW - sleep disorders KW - pain KW - osteoporosis KW - fracture KW - fracture risk assessment tool KW - treat-to-target KW - certolizumab pegol KW - csDMARDs KW - glucocorticoids KW - intra-articular injections KW - DAS 28 KW - ACR response KW - HAQ-DI KW - TNFα KW - golimumab KW - efficacy KW - tolerability KW - immunogenicity KW - methotrexate KW - posology KW - titration KW - oral route KW - subcutaneous route KW - bioavailability KW - effectiveness KW - periodontitis KW - periodontal disease KW - anti-citrullinated protein autoantibodies KW - rheumatoid factor KW - smoking KW - medication KW - Porphyromonas gingivalis KW - Rheumatoid arthritis KW - matrix metalloproteinase 3 KW - infliximab KW - pharmacogenomics KW - anti-TNF KW - personalized medicine KW - baricitinib KW - disease-modifying antirheumatic drugs KW - pain perception KW - outcomes research KW - patient perspective KW - Rheumatoid Arthritis KW - therapy KW - DMARD KW - MTX KW - Tumor Necrosis Factor-Alpha Inhibitors KW - ankylosing spondylitis KW - biosimilar KW - switching KW - synovial fibroblasts KW - cytokine KW - osteoclast KW - herbal medicine KW - methylation KW - next-generation sequencing KW - recovery of function KW - fatigue KW - productivity KW - tofacitinib KW - oral KW - Th1.17 KW - IL-17A KW - IFN-γ, CD73 KW - adenosine KW - psoriatic arthritis KW - regulation KW - pseudoerosions KW - hand KW - foot KW - ultrasonography KW - radiography KW - computed tomography KW - magnetic resonance imaging KW - n/a UR - https://www.unicat.be/uniCat?func=search&query=sysid:139146573 AB - Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA. ER -